Related Experiment Video

Updated: Apr 5, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.7K

PARP inhibitors in the management of breast cancer: current data and future prospects

Luca Livraghi1, Judy E Garber2

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA. luca_livraghi@dfci.harvard.edu.

BMC Medicine
|August 14, 2015
PubMed

Insights

Poly(ADP-ribose) polymerases (PARP) inhibitors show promise for treating cancers with DNA repair defects, such as BRCA-mutated breast and ovarian cancers. This review covers PARP inhibitor development, clinical use, toxicities, resistance, and diagnostics.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Poly(ADP-ribose) polymerases (PARP) are crucial enzymes in DNA damage repair pathways.
  • PARP inhibition is a targeted therapy strategy for cancers with deficient DNA repair mechanisms.
  • This includes cancers with mutations in BRCA1 and BRCA2 genes, common in breast and ovarian cancers.

Purpose of the Study:

  • To review the development and therapeutic potential of PARP inhibitors.
  • To discuss their application as monotherapy and in combination treatments.
  • To summarize associated toxicities, acquired resistance mechanisms, and companion diagnostics.

Main Methods:

  • Literature review of preclinical and clinical studies on PARP inhibitors.
  • Analysis of data from ongoing and completed clinical trials.
  • Synthesis of information on drug development, efficacy, safety, and resistance.

Main Results:

  • PARP inhibitors are effective as single agents and in combination therapies for various cancers.
  • Clinical trials are evaluating these agents in adjuvant, neoadjuvant, and metastatic settings.
  • Understanding resistance mechanisms and companion diagnostics is key for optimizing treatment.

Conclusions:

  • PARP inhibitors represent a significant advancement in targeted cancer therapy, particularly for BRCA-mutated cancers.
  • Further research is ongoing to expand their use and overcome resistance.
  • Companion diagnostics are essential for patient selection and treatment efficacy.

More Related Videos

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

15.7K
Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

30.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.4K